首页> 外文期刊>New Microbes and New Infections >Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF
【24h】

Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF

机译:使用GeneXpert MTB / RIF在多哥进行复治的HIV阳性和HIV阴性患者中多药耐药结核病的患病率

获取原文
           

摘要

Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging.
机译:耐药结核病(TB)在多哥正成为重要的健康问题。从以前治疗过的结核病患者的痰液中,通过GeneXpert MTB / RIF诊断出多药耐药(MDR)结核病的发生率为24%(10/42),而通过常规药物敏感性测试(BACTEC MGIT 960)则诊断为25%(6/24)系统)。这两种检测耐多药结核病的方法之间的一致性非常好。但是,在培养物阴性(33%,14/42)或被污染(9.5%,4/42)的情况下,GeneXpert MTB / RIF的优势是可以快速检测痰液样本中的结核分枝杆菌复合物。 GeneXpert MTB / RIF允许我们估计先前治疗的结核病患者中MDR-TB的患病率,并改善多哥的HIV阳性和阴性患者的TB诊断,在这方面,从痰液样本中培养结核分枝杆菌复合物是一项挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号